DBV Technologies S.A. (DBVT)

NASDAQ: DBVT · IEX Real-Time Price · USD
1.34
0.05 (3.88%)
May 18, 2022 11:04 AM EDT - Market open
Market Cap147.66M
Revenue (ttm)5.31M
Net Income (ttm)-85.07M
Shares Out110.19M
EPS (ttm)-0.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,513
Open1.37
Previous Close1.29
Day's Range1.32 - 1.37
52-Week Range1.15 - 6.47
Beta2.04
AnalystsBuy
Price Target2.70 (+101.5%)
Earnings DateMay 2, 2022

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin...

IndustryBiotechnology
Founded2002
CEODaniel Tasse
Employees92
Stock ExchangeNASDAQ
Ticker SymbolDBVT
Full Company Profile

Financial Performance

In 2021, DBVT's revenue was 5.71 million, a decrease of -49.38% compared to the previous year's 11.28 million. Losses were -97.81 million, -38.70% less than in 2020.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 10 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is 2.7, which is an increase of 101.49% from the latest price.

Price Target
$2.7
(101.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hot Penny Stocks You Need to Know About This Month

Are these penny stocks on your watchlist right now? The post Hot Penny Stocks You Need to Know About This Month  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:CRXTRIG
1 week ago - PennyStocks

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Montrouge, France, May 2, 2022

2 weeks ago - GlobeNewsWire

Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, April 26, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

3 weeks ago - GlobeNewsWire

DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, April 25, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

3 weeks ago - GlobeNewsWire

Ordinary and Extraordinary General Meeting of May 12, 2022

Montrouge, France, April 21, 2022 Ordinary and Extraordinary General Meeting of May 12 , 2022

3 weeks ago - GlobeNewsWire

DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference

2 months ago - GlobeNewsWire

DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates

Montrouge, France, March 3, 2022

2 months ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming AAAAI 2022 Congress

Montrouge, France, February 22, 2022

2 months ago - GlobeNewsWire

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Montrouge, France, February 14, 2022

3 months ago - GlobeNewsWire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATION Montrouge, France, January 21, 2022

3 months ago - GlobeNewsWire

DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

Montrouge, France, January 7, 2022

4 months ago - GlobeNewsWire

Why DBV Technologies Stock Is Down Sharply on Tuesday

The road ahead for the peanut allergy treatment Viaskin Peanut is going to be rockier than investors had hoped.

4 months ago - The Motley Fool

DBV Technologies To Conduct New Pivotal Trial For Peanut Allergy Patch, Shares Plunge To 52-Week Low

After reviewing the FDA's information requests and considering all other options, DBV Technologies (NASDAQ: DBVT) has decided not to pursue the sequential approach to develop Viaskin Peanut (allergen up...

4 months ago - Benzinga

DBV Technologies Provides Update on Investigational Viaskin™ Peanut

Montrouge, France, December 20, 2021

4 months ago - GlobeNewsWire

DBV Technologies to Participate in an Upcoming Investor Conference

Montrouge, France, November 24, 2021

5 months ago - GlobeNewsWire

Down 42.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

6 months ago - Zacks Investment Research

Why DBV Technologies Stock Is Jumping Today

The company plans to announce new data for its experimental peanut allergy drug this week.

6 months ago - The Motley Fool

Down 36.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

6 months ago - Zacks Investment Research

DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021

Montrouge, France, November 1, 2021

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

New York, New York--(Newsfile Corp. - October 29, 2021) -   Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. ("DBV" or the "Company") (NASDAQ: DBVT). Such investors ...

6 months ago - Newsfile Corp